LXEO · Insider Trading
Lexeo Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by LXEO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-28 | Louis Edward Tamayo | Chief Financial Officer | A | +54,750 deriv. | — |
| 2026-09-28 | Narinder Pal Bhalla | Chief Medical Officer | A | +2,714 | +$9.71K |
| 2026-09-28 | Richard Nolan Townsend | Chief Executive Officer | A | +2,306 | +$6.10K |
| 2026-09-28 | Jose Manuel Otero | Chief Operating Officer | A | +2,110 | +$5.58K |
| 2026-08-19 | Jose Manuel Otero | Chief Operating Officer | Sell | −1,304 | −$6.46K |
| 2026-08-19 | Louis Edward Tamayo | Chief Financial Officer | Sell | −4,117 | −$20.20K |
| 2026-08-19 | Richard Nolan Townsend | Chief Executive Officer | Sell | −3,345 | −$16.56K |
| 2026-07-01 | Louis Edward Tamayo | Chief Financial Officer | MIXED | +7,359 | −$20.84K |
| 2026-07-01 | Narinder Pal Bhalla | Chief Medical Officer | MIXED | +32,694 | −$98.59K |
| 2026-07-01 | Jose Manuel Otero | Chief Operating Officer | MIXED | +7,394 | −$20.90K |
| 2026-07-01 | Richard Nolan Townsend | Chief Executive Officer | MIXED | +41,053 | −$116.24K |
| 2026-06-29 | Reinaldo M Diaz | Director | A | +35,000 deriv. | — |
| 2026-06-29 | Timothy Van Hauwermeiren | Director | A | +35,000 deriv. | — |
| 2026-06-29 | Steven Altschuler | Director | A | +35,000 deriv. | — |
| 2026-06-29 | Mette Kirstine Agger | Director | A | +35,000 deriv. | — |
| 2026-06-29 | Tolga Tanguler | Director | A | +35,000 deriv. | — |
| 2026-06-29 | Paula H Cholmondeley | Director | A | +35,000 deriv. | — |
| 2026-06-29 | Brenda Cooperstone | Director | A | +35,000 deriv. | — |
| 2026-05-20 | Jose Manuel Otero | Chief Operating Officer | Sell | −1,302 | −$6.61K |
| 2026-05-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | −3,342 | −$16.93K |
| 2026-04-07 | Richard Nolan Townsend | Chief Executive Officer | Sell | −55,000 | −$313.14K |
| 2026-03-17 | Jose Manuel Otero | Chief Operating Officer | A | +5,930 | +$15.68K |
| 2026-03-17 | Richard Nolan Townsend | Chief Executive Officer | A | +2,623 | +$6.94K |
| 2026-02-20 | Jose Manuel Otero | Chief Operating Officer | Sell | −721 | −$6.68K |
| 2026-02-20 | Jose Manuel Otero | Chief Operating Officer | Sell | −3,016 | −$19.29K |
| 2026-02-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | −10,173 | −$64.92K |
| 2026-02-17 | Narinder Pal Bhalla | Chief Medical Officer | A | +49,500 | — |
| 2026-02-06 | Louis Edward Tamayo | Chief Financial Officer | A | +44,665 | — |
| 2026-02-06 | Richard Nolan Townsend | Chief Executive Officer | A | +161,665 | — |
| 2026-02-06 | Jose Manuel Otero | Chief Operating Officer | A | +65,000 | — |
| 2025-11-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | −1,127 | −$10.45K |
| 2025-11-20 | Eric Adler | Chief Medical Officer | Sell | −615 | −$5.70K |
| 2025-11-20 | Jose Manuel Otero | Chief Technical Officer | Sell | −721 | −$6.68K |
| 2025-11-20 | Jenny Robertson | Chief Legal Officer | Sell | −549 | −$5.09K |
| 2025-11-20 | Tai Sandi See | Chief Development Officer | Sell | −386 | −$3.58K |
| 2025-10-17 | Jenny Robertson | Chief Legal Officer | MIXED | +6,374 | −$31.53K |
| 2025-10-17 | Richard Nolan Townsend | Chief Executive Officer | MIXED | +19,867 | −$117.44K |
| 2025-10-17 | Eric Adler | Chief Medical Officer | MIXED | +6,188 | −$30.24K |
| 2025-10-17 | Tai Sandi See | Chief Development Officer | MIXED | +7,002 | −$34.77K |
| 2025-10-17 | Jose Manuel Otero | Chief Technical Officer | MIXED | +3,825 | −$18.91K |
| 2025-09-16 | Richard Nolan Townsend | Chief Executive Officer | A | +2,193 | +$5.80K |
| 2025-09-10 | Richard Nolan Townsend | Chief Executive Officer | Sell | −1,115 | −$5.20K |
| 2025-09-03 | Louis Edward Tamayo | Chief Financial Officer | A | +45,000 | — |
| 2025-08-20 | Eric Adler | Chief Medical Officer | Sell | −608 | −$2.84K |
| 2025-08-20 | Jenny Robertson | Chief Legal Officer | Sell | −542 | −$2.53K |
| 2025-08-20 | Tai Sandi See | Chief Development Officer | Sell | −382 | −$1.78K |
| 2025-08-20 | Richard Nolan Townsend | Chief Executive Officer | Sell | −2,735 | −$12.77K |
| 2025-08-20 | Jose Manuel Otero | Chief Technical Officer | Sell | −2,848 | −$13.29K |
| 2025-06-30 | Brenda Cooperstone | Director | A | +25,000 deriv. | — |
| 2025-06-30 | Paula H Cholmondeley | Director | A | +25,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Richard Nolan Townsend | Chief Executive Officer | 376,778 | $1.11M |
| Jose Manuel Otero | Chief Operating Officer | 138,288 | $406.57K |
| Louis Edward Tamayo | Chief Financial Officer | 92,907 | $273.15K |
| Narinder Pal Bhalla | Chief Medical Officer | 84,908 | $249.63K |
| Eric Adler | Chief Medical Officer | 72,646 | $213.58K |
| Jenny Robertson | Chief Legal Officer | 68,381 | $201.04K |
| Tai Sandi See | Chief Development Officer | 65,476 | $192.50K |
| Kyle Rasbach | Chief Financial Officer | 40,875 | $120.17K |
| Paula H Cholmondeley | Director | 30,627 | $90.04K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LXEO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.